EGFR and adenocarcinoma: Several trials have shown that non‐mucinous tumours, especially in adenocarcinomas with pathological types of papillary, micropapillary and adherent growth characteristics, have a high EGFR mutation rate, and the EGFR mutation rate in AIS/MIA/LPA can even be as high as 45%.6, 7, 8